Efficacy of ivabradine in combination therapy for complicated acute coronary syndrome in patients with type 2 diabetes mellitus


Aim: To study the effect of ivabradine (coraxan, Servier) as part of combination therapy on the clinical manifestations of acute left ventricular failure (ALVF) in Braunwald class II-IIIB unstable angina in patients with type 2 diabetes mellitus (T2DM).
Subjects and methods. Thirty-six T2DM patients (mean age 56 ± 4.3 years) with a diagnosis of acute coronary syndrome were examined. Eighteen healthy individuals were examined as an age- and gender-matched control group. Metabolic, hemodynamic, and electrophysiological parameters were studied in all the patients on hospital stay days 1 and 5.
Results. Ivabradine used in combination therapy for unstable angina caused reductions in the clinical manifestations of ALVF, heart rate, the number of myocardial ischemic episodes. In the ivabradine-treated patients, left ventricular ejection fraction showed a significant trend for increase. No adverse reactions were recorded.
Conclusion. Ivabradine therapy demonstrated antiischemic and antianginal efficiencies and a good tolerability, without leading to the development of tolerance and without being followed by the development of the withdrawal syndrome.

About the authors

Arkadiy Ivanovich Kondrat'ev

Email: arca_2004@mail.ru

Vladimir Terent'evich Dolgikh

Aleksandr Olegovich Stotskiy

A I Kondratyev

Town Emergency Care Clinical Hospital One

Town Emergency Care Clinical Hospital One

V T Dolgikh

Omsk State Medical Academy, Ministry of Health and Social Development

Omsk State Medical Academy, Ministry of Health and Social Development

A O Stotsky

Town Emergency Care Clinical Hospital One

Town Emergency Care Clinical Hospital One


  1. Терещенко С. Н., Косицына И. В., Голубев А. В. Возможность применения ивабрадина в комплексной терапии острого коронарного синдрома. Кардиология 2008; 7: 10- 13.
  2. DiFrancesco D. If current inhibitors: propeties of drug channel interraction. In: Fox K. ed. Selective and specific If channel inhibition in cardiology. London: Science Press Ltd; 2004; vol. 5: 1-13.
  3. Seccareccia F., Pannozzo F., Dima F. et al. Heart rate as a predictor of mortality: the MATISS Project. Am. J. Publ. Hlth 2001; 91 (7): 1258-1263.
  4. Diaz A., Bourassa M. G., Guertin M.-C. et al. Long-term prognostic value of resting heart rate in patients with suspected of proven coronary artery disease. Eur. Heart. J. 2005; 26 (6): 967-974.
  5. Kjekshus J. Importance of heart rate in determing beta-blocker efficacy in acute and long-term myocardial infarction intervention trials. Am. J. Cardiol. 1986; 57 (6): 43F-49F.
  6. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II-DAVIT-II). Am. J. Cardiol. 1999; 66 (5): 779-785.
  7. Шальнова С. А., Деев А. Д., Оганов Р. Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология 2005; 10: 45-50.
  8. Манешина О. А., Белоусов Ю. Б., Ерофеева С. Б. Место ивабрадина - первого If-ингибитора избирательного и специфического действия, в лечении сердечно-сосудистых заболеваний. Качеств. клин. практика 2006; 1: 10-22.
  9. Mulder P., Barbie S., Chagraoui A. et al. Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004; 109 (6): 1674-1679.
  10. Camm A. J., Lau C. P. Electrophysiological effects of a single intravenous administration of ivabradin (S 16257) in adult patient with normal electrophysiology. Drug R&D 2003; 6 (4): 83-89.
  11. Lenfant J., Bois P. Selective and specific If inhibition in cardiovascular disease. In: B. N. Singh, P. M. Vanhoutte (eds.) Lippincott Williams and Wilkins; 2003. Phyladelphia p. 79.
  12. Bucchi A., Baruscotti M., DiFrancesco D. Current-dependent block of rabbit sino-atrial node If channels by ivabradin. J. Gen Physiol. 2002; 120 (4): 1-13.
  13. Monnet X., Colin P., Ghaleh B. et al. Heart rate reduction during exercise-induced myocardial ischemia and stunning. Eur. Heart J. 2004; 25 (9): 579-586.
  14. Tardif J. C., Ford I., Tendera M. et al. On behalf of INITIATIVE study investigators group. Antianginal and anti-ischemic effects of the If current inhibitor ivabradine compared to atenolol as monotherapies in patients with chronic stable angina. Eur. Heart J. 2003; 24: Abstr. 186.
  15. Vilaine J. P., Bidouard J. P., Lesage L. et al. Anti-ischemic effects of ivabradin, a selective heart-rate reducing agent, in exercise-induced myocardial ischemia in pigs. J. Cardiovasc. Pharmacol. 2003; 42 (5): 688-696.
  16. Ruzyllo W., Ford L, Tendera M. et al. Antianginal and anti-ischemic effects of If current inhibitor ivabradine compared to amlodipine as monotherapy in patients with chronic stable angina: a 3-month randomized, controlled, double-blind, multi-center trial. Eur. Heart J. 2004; 25: A878.
  17. Дедов И. И., Александров А. А. Диабетическое сердце: Causa Magna. Сердце 2004; 3: 5-8.
  18. Gundersen Т., Syekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983; 6: 285- 290.
  19. Кремнева Л. В., Шалаев С. В. Гипергликемия у больных острым коронарным синдромом. Атеротромбоз 2009; 1: 86-94.
  20. Lowel H., Koenig W., Engel S. et al. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population - based myocardial infarction register follow-up study. Diabetologia 2000; 43 (2): 218-226.
  21. Malmberg К., Herlitz J., Hjalmarson A., Ryden L. Effects of metoprolol on mortality and late infarction in diabetic with suspected acute myocardial infarction. Retrospective data from two large studies. Eur. Heart J. 1989; 10: 423-428.



Abstract - 155


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2010 Kondrat'ev A.I., Dolgikh V.T., Stotskiy A.O., Kondratyev A.I., Dolgikh V.T., Stotsky A.O.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies